STML - Stemline Therapeutics, Inc.
| Previous Close | 15.50 |
| Open | 15.45 |
| Bid | 16.00 x 900 |
| Ask | 16.10 x 1100 |
| Day's Range | 15.35 - 16.20 |
| 52 Week Range | 7.30 - 20.55 |
| Volume | 39,828 |
| Avg. Volume | 234,576 |
| Market Cap | 461.086M |
| Beta | 1.02 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire•22 days ago
Stemline Therapeutics Announces Completion of Rolling BLA Submission for ELZONRIS™ (tagraxofusp; SL-401) for the Treatment of BPDCN
NEW YORK, June 25, 2018-- Stemline Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel oncology therapeutics, announced today that it has completed submission of a rolling Biologics ...
- ACCESSWIRE•28 days ago
Biotechnology Firm PPCB, Shows Great Potential
Propanc BioPharma, Inc ( PPCB ) Market Cap: 2.4 M, current share price: $0.07 HENDERSON, NV / ACCESSWIRE / June 19, 2018 / Propanc Biopharma Inc. , a clinical stage biopharmaceutical company focusing on ...
- GlobeNewswire•29 days ago
Stemline Therapeutics Announces Positive Clinical Data from ELZONRISTM (tagraxofusp; SL-401) Trials in BPDCN, CMML and MF Delivered at the EHA Congress
NEW YORK, June 18, 2018-- Stemline Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel oncology therapeutics, announced today that positive clinical data from ELZONRIS TM trials ...
- GlobeNewswire•last month
Stemline Therapeutics Announces Presentation of ELZONRIS™ (tagraxofusp; SL-401) Preclinical Data in Systemic Sclerosis, an Autoimmune Disorder, at EULAR Congress
NEW YORK, June 15, 2018-- Stemline Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel oncology therapeutics, announced today that ELZONRIS™ preclinical data in the autoimmune ...
- GlobeNewswire•last month
Stemline Therapeutics Announces Three ELZONRIS™ (tagraxofusp; SL-401) Clinical Presentations, Including an Oral Presentation, at the EHA Congress
NEW YORK, June 14, 2018-- Stemline Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel oncology therapeutics, announced that ELZONRIS TM will be the subject of three clinical ...
- GlobeNewswire•last month
Stemline Therapeutics Announces Positive Data Presentations on SL-701 and SL-801 at ASCO
NEW YORK, June 05, 2018-- Stemline Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel oncology therapeutics, announced today that positive data from the SL-701 and SL-801 clinical ...
- ACCESSWIRE•2 months ago
Wired News - Stemline Therapeutics' SL-401 BPDCN Program Selected for Clinical Presentations at Upcoming EHA Congress
LONDON, UK / ACCESSWIRE / May 22, 2018 / If you want access to our free research report on Stemline Therapeutics, Inc. (NASDAQ: STML), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=STML as the Company's latest news hit the wire. On May 18, 2018, the Company announced that its SL-401 will be the subject of three clinical presentations, including an oral presentation on the pivotal blastic plasmacytoid dendritic cell neoplasm (BPDCN) program, at the upcoming 23rd Congress of the European Hematology Association (EHA), to be held from June 14-17, 2018, in Stockholm, Sweden. Updated data from the ongoing Phase-2 trial in chronic myelomonocytic leukemia (CMML) and myelofibrosis (MF) will also be presented.
- GlobeNewswire•2 months ago
Stemline Therapeutics Announces Three SL-401 Clinical Presentations, Including an Oral Presentation, at the Upcoming EHA Congress
NEW YORK, May 18, 2018-- Stemline Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel oncology therapeutics, announced today that SL-401 will be the subject of three clinical ...
- GlobeNewswire•2 months ago
Stemline Therapeutics Announces Presentation of SL-801 and SL-701 Clinical Data at the Upcoming ASCO Annual Meeting
NEW YORK, May 17, 2018-- Stemline Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel oncology therapeutics, announced today that clinical data from SL-801 and SL-701 trials ...
- GlobeNewswire•2 months ago
Stemline Therapeutics Reports First Quarter 2018 Financial Results
NEW YORK, May 09, 2018-- Stemline Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel oncology therapeutics, announced today financial results for the quarter ended March 31, ...
- Business Wire•2 months ago
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Stemline Therapeutics, Inc.
Levi & Korsinsky announces it has commenced an investigation of Stemline Therapeutics, Inc. concerning possible breaches of fiduciary duty. To obtain additiona
- PR Newswire•3 months ago
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Stemline Therapeutics, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
NEW YORK , May 1, 2018 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim ...
- GlobeNewswire•3 months ago
Report: Exploring Fundamental Drivers Behind Agilysys, Editas Medicine, The ExOne, Central Garden & Pet, Quality, and Stemline Therapeutics — New Horizons, Emerging Trends, and Upcoming Developments
NEW YORK, April 30, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
- GlobeNewswire•3 months ago
Stemline Therapeutics Announces Clinical Presentations of SL-801 and SL-701 at the Upcoming ASCO Annual Meeting
NEW YORK, April 26, 2018-- Stemline Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel oncology therapeutics, announced today that clinical data from SL-801 and SL-701 trials ...
- ACCESSWIRE•3 months ago
Wired News – Stemline Therapeutics Initiates Rolling BLA Submission for SL-401
Stock Monitor: Cyclacel Pharma Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 09, 2018 / Active-Investors.com has just released a free research report on Stemline Therapeutics, Inc. (NASDAQ: STML ...